Update on Precision Medicine in Breast Cancer

Jasgit C. Sachdev, Ana C. Sandoval, Mohammad Jahanzeb

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Precision medicine approaches have found applications in the treatment of several tumor types and have led to rapid advancement in the number of available therapies for some difficult-to-treat diseases. In comparison to tumors like EGFR-mutated lung cancer, and BRAF-mutated melanoma for example, precision medicine in breast cancer is still in its infancy despite the much earlier identification of targets like ER and HER2. Though significant progress has been made in new therapies for hormone-receptor-positive and HER2-positive breast cancers, identification of molecular heterogeneity and lack of other valid reproducible targets in triple-negative breast cancer remain a challenge. In this chapter, we outline the recent advances in technology and targeted treatments for breast cancer, the remaining challenges and ongoing efforts to address these to make precision medicine a reality for all breast cancer patients.

Original languageEnglish (US)
Title of host publicationCancer Treatment and Research
PublisherSpringer International Publishing
Pages45-80
Number of pages36
DOIs
StatePublished - Jan 1 2019

Publication series

NameCancer Treatment and Research
Volume178
ISSN (Print)0927-3042

Fingerprint

Precision Medicine
Breast Neoplasms
Triple Negative Breast Neoplasms
Therapeutics
Melanoma
Lung Neoplasms
Neoplasms
Hormones
Technology

Keywords

  • Breast cancer
  • Immunotherapy
  • Multi-omic profiling
  • Targeted therapy
  • Triple-negative breast cancer (TNBC)

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Sachdev, J. C., Sandoval, A. C., & Jahanzeb, M. (2019). Update on Precision Medicine in Breast Cancer. In Cancer Treatment and Research (pp. 45-80). (Cancer Treatment and Research; Vol. 178). Springer International Publishing. https://doi.org/10.1007/978-3-030-16391-4_2

Update on Precision Medicine in Breast Cancer. / Sachdev, Jasgit C.; Sandoval, Ana C.; Jahanzeb, Mohammad.

Cancer Treatment and Research. Springer International Publishing, 2019. p. 45-80 (Cancer Treatment and Research; Vol. 178).

Research output: Chapter in Book/Report/Conference proceedingChapter

Sachdev, JC, Sandoval, AC & Jahanzeb, M 2019, Update on Precision Medicine in Breast Cancer. in Cancer Treatment and Research. Cancer Treatment and Research, vol. 178, Springer International Publishing, pp. 45-80. https://doi.org/10.1007/978-3-030-16391-4_2
Sachdev JC, Sandoval AC, Jahanzeb M. Update on Precision Medicine in Breast Cancer. In Cancer Treatment and Research. Springer International Publishing. 2019. p. 45-80. (Cancer Treatment and Research). https://doi.org/10.1007/978-3-030-16391-4_2
Sachdev, Jasgit C. ; Sandoval, Ana C. ; Jahanzeb, Mohammad. / Update on Precision Medicine in Breast Cancer. Cancer Treatment and Research. Springer International Publishing, 2019. pp. 45-80 (Cancer Treatment and Research).
@inbook{ec1ba2aa2c5646e38179b40aba6a9f30,
title = "Update on Precision Medicine in Breast Cancer",
abstract = "Precision medicine approaches have found applications in the treatment of several tumor types and have led to rapid advancement in the number of available therapies for some difficult-to-treat diseases. In comparison to tumors like EGFR-mutated lung cancer, and BRAF-mutated melanoma for example, precision medicine in breast cancer is still in its infancy despite the much earlier identification of targets like ER and HER2. Though significant progress has been made in new therapies for hormone-receptor-positive and HER2-positive breast cancers, identification of molecular heterogeneity and lack of other valid reproducible targets in triple-negative breast cancer remain a challenge. In this chapter, we outline the recent advances in technology and targeted treatments for breast cancer, the remaining challenges and ongoing efforts to address these to make precision medicine a reality for all breast cancer patients.",
keywords = "Breast cancer, Immunotherapy, Multi-omic profiling, Targeted therapy, Triple-negative breast cancer (TNBC)",
author = "Sachdev, {Jasgit C.} and Sandoval, {Ana C.} and Mohammad Jahanzeb",
year = "2019",
month = "1",
day = "1",
doi = "10.1007/978-3-030-16391-4_2",
language = "English (US)",
series = "Cancer Treatment and Research",
publisher = "Springer International Publishing",
pages = "45--80",
booktitle = "Cancer Treatment and Research",

}

TY - CHAP

T1 - Update on Precision Medicine in Breast Cancer

AU - Sachdev, Jasgit C.

AU - Sandoval, Ana C.

AU - Jahanzeb, Mohammad

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Precision medicine approaches have found applications in the treatment of several tumor types and have led to rapid advancement in the number of available therapies for some difficult-to-treat diseases. In comparison to tumors like EGFR-mutated lung cancer, and BRAF-mutated melanoma for example, precision medicine in breast cancer is still in its infancy despite the much earlier identification of targets like ER and HER2. Though significant progress has been made in new therapies for hormone-receptor-positive and HER2-positive breast cancers, identification of molecular heterogeneity and lack of other valid reproducible targets in triple-negative breast cancer remain a challenge. In this chapter, we outline the recent advances in technology and targeted treatments for breast cancer, the remaining challenges and ongoing efforts to address these to make precision medicine a reality for all breast cancer patients.

AB - Precision medicine approaches have found applications in the treatment of several tumor types and have led to rapid advancement in the number of available therapies for some difficult-to-treat diseases. In comparison to tumors like EGFR-mutated lung cancer, and BRAF-mutated melanoma for example, precision medicine in breast cancer is still in its infancy despite the much earlier identification of targets like ER and HER2. Though significant progress has been made in new therapies for hormone-receptor-positive and HER2-positive breast cancers, identification of molecular heterogeneity and lack of other valid reproducible targets in triple-negative breast cancer remain a challenge. In this chapter, we outline the recent advances in technology and targeted treatments for breast cancer, the remaining challenges and ongoing efforts to address these to make precision medicine a reality for all breast cancer patients.

KW - Breast cancer

KW - Immunotherapy

KW - Multi-omic profiling

KW - Targeted therapy

KW - Triple-negative breast cancer (TNBC)

UR - http://www.scopus.com/inward/record.url?scp=85067675223&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067675223&partnerID=8YFLogxK

U2 - 10.1007/978-3-030-16391-4_2

DO - 10.1007/978-3-030-16391-4_2

M3 - Chapter

T3 - Cancer Treatment and Research

SP - 45

EP - 80

BT - Cancer Treatment and Research

PB - Springer International Publishing

ER -